Drug Trial Radar · NCT05646836
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 21, 2023
Primary completion
Nov 18, 2026
Study completion Nov 18, 2026
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
XmAb24306Drug
XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
TocilizumabDrug
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 3 years
Locations
13 sites in 7 countries. Site status is shown where the registry gives one.
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Sygehus Lillebaelt - Vejle Sygehus
Vejle, Denmark
Evangelismos General Hospital of Athens
Athens, Greece
University of Athens, Hematological Clinic,
Athens, Greece
Rabin Medical Center-Beilinson Campus
Petah Tikva, Israel
Tel Aviv Sourasky Medical Center PPDS
Tel Aviv, Israel
Oslo University Hospital Rikshospitalet
Oslo, Norway
Severance Hospital, Yonsei University
Seoul, South Korea
Asan Medical Center - PPDS
Seoul, South Korea
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.